National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States
04 March 2021
Treating patients with infections due to multidrug-resistant pathogens often requires substantial healthcare resources. The purpose of this study was to report estimates of the healthcare costs associated with infections due to multidrug-resistant bacteria in the United States (US).
We found that antimicrobial-resistant infections led to substantial healthcare costs.
Further reading: Clinical Infectious Diseases
Author(s): Richard E Nelson, Kelly M Hatfield, Hannah Wolford, Matthew H Samore, R Douglas Scott, II, Sujan C Reddy, Babatunde Olubajo, Prabasaj Paul, John A Jernigan, James Baggs
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
EADA 2023
Emerging Antimicrobials and Diagnostics in AMR 2023
International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November
